Sermorelin
NOT FDA APPROVEDGrowth-hormone-releasing hormone analog
Also known as: GRF 1-29, Geref (discontinued)
Previously FDA approved (Geref, discontinued in 2008 for commercial reasons). Now available only as a physician-prescribed compounded product, not an approved drug.
A real evidence base, with gaps
- Regulatory standing. Sold as a research chemical, not approved
- Human trials. Backed by controlled human studies
- Registered human trials. 27 registered studies on ClinicalTrials.gov, most advanced Phase 4
- 1 cited source. Cited references provided
A read on the weight of evidence and regulatory standing behind this compound. It is not a safety score, not a purity or quality rating, and not medical advice. It is not a claim that this compound treats, cures, or prevents any condition, and not an endorsement or a recommendation to buy or use it. A low score means the evidence is thin — not that a product is unsafe; a high score means the evidence is strong — not that anyone should take it. PLOBT is independent and takes no money from any vendor; no company can pay to change this score.
Proven: it stimulates the body's own growth-hormone release and was historically approved to diagnose/treat GH deficiency. NOT established: the anti-aging and body-composition benefits it is currently marketed for.
What it is
A GHRH analog. It stimulates natural, pulsatile GH release rather than replacing GH directly.
What the research says
Historically FDA approved for GH-related indications before the product was discontinued.
The main marketed use today. Not well established in controlled trials.
Published literature
Live from Europe PMC. Peer-reviewed papers discussing Sermorelin in their title or abstract, most-cited first. This is how much has been published — not how much is proven in humans. It counts landmark trials, animal studies and reviews alike.
PEGylation of growth hormone-releasing hormone (GRF) analogues.
Perinatal growth hormone (GH) physiology: effect of GH-releasing factor on maternal and fetal secretion of pituitary and placental GH.
Expanded test method for peptides >2 kDa employing immunoaffinity purification and LC-HRMS/MS.
Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS.
Registered human trials
Live from ClinicalTrials.gov, the US NIH registry of human studies, refreshed daily. Counts studies where Sermorelin is the intervention being tested.
TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy
VRS-317 in Adult Subjects With Growth Hormone Deficiency
Effect of Short Term Growth Hormone Releasing Hormone in Healthy Men
Study of Intranasal Octreotide (DP1038) in Healthy Adult Volunteers
FDA recalls & enforcement
Sermorelin has no FDA recall or drug record at all — because it is not an FDA-regulated drug. That absence is not a safety signal. It means this compound is sold outside the system that inspects, tracks and recalls unsafe products in the first place.
Source: openFDA drug enforcement.
What people log it for
Descriptive, based on what users track. Not an endorsement or a suggested use.
Risks & unknowns
- No currently approved product: quality depends on the compounding pharmacy.
- GH/IGF-1 elevation carries theoretical growth-signalling risks.
Doses reported in studies & protocols
Compounded protocols vary. This is not a recommendation.
Purity reality
Compounded product quality varies by pharmacy.
None yet. PLOBT does not publish invented purity numbers. Real third-party COA data, mapped to vendor and batch, is in development — and it is the one thing we refuse to fake.
Sources
We cite peer-reviewed journals, PubMed/PMC, FDA and university sources, not vendor marketing.